Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.39 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.34 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20960018 | 0.93 | POLRMT (0.58) | POLRMTP2RY2P2RY1P2RY11P2RY4 | |
| SCHEMBL17106741 | 0.88 | POLRMT (0.47) | POLRMTP2RY2P2RY1P2RY11P2RX1 | |
| SCHEMBL19412771 | 0.87 | POLRMT (0.61) | POLRMTP2RY2P2RY1P2RY11P2RY4 | |
| SCHEMBL19779239 | 0.87 | POLRMT (0.58) | POLRMTP2RY2P2RY1P2RY11P2RY4 | |
| SCHEMBL16708503 | 0.85 | POLRMT (0.61) | POLRMTP2RY2P2RY1P2RY11P2RX1 | |
| SCHEMBL20834806 | 0.80 | POLRMT (0.59) | POLRMTP2RY2P2RY1P2RY11P2RX1 | |
| SCHEMBL16708507 | 0.80 | POLRMT (0.69) | POLRMTP2RY2P2RY1P2RY11P2RX1 | |
| SCHEMBL17106845 | 0.80 | POLRMT (0.37) | POLRMT | |
| SCHEMBL17130417 | 0.80 | POLRMT (0.37) | POLRMT | |
| SCHEMBL20960149 | 0.80 | POLRMT (0.58) | POLRMTP2RY2P2RY1P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015143712-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | POLRMT 7/4885P2RY2 4251/4885P2RY1 3360/4885 |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | POLRMT 306/4885P2RY2 2514/4885P2RY1 1933/4885 |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | POLRMT 306/4885P2RY2 2514/4885P2RY1 1933/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | POLRMT 7/4885P2RY2 4251/4885P2RY1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.